1.
PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy
by Bodei, Lisa
European journal of nuclear medicine and molecular imaging, 2018-02-26, Vol.45 (7), p.1155-1169
2.
177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study
by Paganelli, Giovanni
European journal of nuclear medicine and molecular imaging, 2014-03-11, Vol.41 (10), p.1845-1851
3.
Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index
by Nicolini, Silvia
European journal of nuclear medicine and molecular imaging, 2018-02-01, Vol.45 (6), p.923-930
4.
Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors
by Sansovini, Maddalena
Neuroendocrinology, 2013, Vol.97 (4), p.347-354
5.
Insights into intradialytic atrial fibrillation onset mechanisms
by Genovesi, Simonetta
Heart (British Cardiac Society), 2014-08, Vol.100 (16), p.1302-1302
6.
Comment on the Paper: ‘Novel Approach to Estimate Kidney and Cyst Volumes Using Mid-Slice Magnetic Resonance Images in Polycystic Kidney Disease
by Corsi, Cristiana
American journal of nephrology, 2014-03, Vol.39 (2), p.163-164
7.
Assessment of Kidney Volume in Polycystic Kidney Disease Using Magnetic Resonance Imaging without Contrast Medium
by Mignani, Renzo
American journal of nephrology, 2011-03, Vol.33 (2), p.176-184
8.
Alterations of atrial electrophysiology related to hemodialysis session: insights from a multiscale computer model
by Krueger, Martin Wolfgang, Dipl.-Ing
Journal of electrocardiology, 2011, Vol.44 (2), p.176-183
9.
Single bone metastasis from adenocarcinoma of the lacrimal gland: a case report
by Ricci, Marianna
Future oncology (London, England), 2014-08-01, Vol.10 (10), p.1735-1739
10.
PRRT genomic signature in blood for prediction of Lu-177-octreotate efficacy
by Bodei, L
European journal of nuclear medicine and molecular imaging, 2018, Vol.45 (7), p.1155-1169
11.
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours
by Severi, Stefano
European journal of nuclear medicine and molecular imaging, 2013-02-27, Vol.40 (6), p.881-888
12.
Delta-like ligand 3 (DLL3): an attractive actionable target in tumors with neuroendocrine origin
by Ranallo, Nicoletta
Expert review of anticancer therapy, 2022-06-03, Vol.22 (6), p.597-603
13.
Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE
by Sansovini, Maddalena
European journal of nuclear medicine and molecular imaging, 2016-10-04, Vol.44 (3), p.490-499
14.
Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET
by Ianniello, Annarita
European journal of nuclear medicine and molecular imaging, 2015-11-27, Vol.43 (6), p.1040-1046
15.
Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC
by Severi, Stefano
European journal of nuclear medicine and molecular imaging, 2015-06-26, Vol.42 (13), p.1955-1963
16.
Investigation of receptor radionuclide therapy with 177.sup.Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index
by Nicolini, Silvia
European journal of nuclear medicine and molecular imaging, 2018-06-01, Vol.45 (6), p.923
17.
Yttrium-labelled peptides for therapy of NET
by Bodei, Lisa
European journal of nuclear medicine and molecular imaging, 2012-03-03, Vol.39 (Suppl 1), p.93-102
18.
PRRT genomic signature in blood for prediction of 177.sup.Lu-octreotate efficacy
by Bodei, Lisa
European journal of nuclear medicine and molecular imaging, 2018-07-01, Vol.45 (7), p.1155
19.
Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE
by Sansovini, Maddalena
European journal of nuclear medicine and molecular imaging, 2016-11-02, Vol.44 (2), p.352-352
20.
Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with super(177)Lu-D OTATATE
by Sansovini, Maddalena
European journal of nuclear medicine and molecular imaging, 2017-03-01, Vol.44 (3), p.490-499
